Heart failure after treatment for breast cancer

ConclusionsIn absence of anthracyclines, breast cancer radiotherapy was not associated with increased HF risk. Strongly elevated HF risks were observed after treatment with anthracyclines and also after treatment with trastuzumab. The benefits of these systemic treatments usually exceed the risks of HF, but our results emphasize the need to support ongoing efforts to evaluate preventative strategies.

Source: European Journal of Heart Failure - November 11, 2019 Category: Cardiology Authors: Naomi B. Boekel, Fran K. Duane, Judy N. Jacobse, Michael Hauptmann, Michael Schaapveld, Gabe S. Sonke, Jourik A. Gietema, Maartje J. Hooning, Caroline M. Seynaeve, Angela H.E.M. Maas, Sarah C. Darby, Berthe M.P. Aleman, Carolyn W. Taylor, Flo Tags: Research Article Source Type: research